Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents

Overview

Journal Endocr Rev

Publisher Oxford University Press

Specialty Endocrinology

Date 2019 May 4

PMID 31050706

Citations 162

Authors

Antonino Di Pino

Ralph A DeFronzo

Affiliations

Soon will be listed here.

Abstract

Patients with type 2 diabetes mellitus (T2DM) are at high risk for macrovascular complications, which represent the major cause of mortality. Despite effective treatment of established cardiovascular (CV) risk factors (dyslipidemia, hypertension, procoagulant state), there remains a significant amount of unexplained CV risk. Insulin resistance is associated with a cluster of cardiometabolic risk factors known collectively as the insulin resistance (metabolic) syndrome (IRS). Considerable evidence, reviewed herein, suggests that insulin resistance and the IRS contribute to this unexplained CV risk in patients with T2DM. Accordingly, CV outcome trials with pioglitazone have demonstrated that this insulin-sensitizing thiazolidinedione reduces CV events in high-risk patients with T2DM. In this review the roles of insulin resistance and the IRS in the development of atherosclerotic CV disease and the impact of the insulin-sensitizing agents and of other antihyperglycemic medications on CV outcomes are discussed.

Citing Articles

The Association of the Metabolic Score for Insulin Resistance (METS-IR) with Prehypertension in Normoglycemic Individuals.

Alogaili M, Alsallami A Int J Endocrinol Metab. 2025; 22(2):e145894.

PMID: 40071249 PMC: 11892513. DOI: 10.5812/ijem-145894.

Association between estimated glucose disposal rate and incident cardiovascular disease in a population with Cardiovascular-Kidney-Metabolic syndrome stages 0-3: insights from CHARLS.

Tan Z, Zhou D, Tang Y, Huo G Front Cardiovasc Med. 2025; 12:1537774.

PMID: 40066350 PMC: 11891229. DOI: 10.3389/fcvm.2025.1537774.

Early prediction of postpartum dyslipidemia in gestational diabetes using machine learning models.

Jiang Z, Chen X, Lai Y, Liu J, Ye X, Chen P Sci Rep. 2025; 15(1):8028.

PMID: 40055456 PMC: 11889255. DOI: 10.1038/s41598-025-92299-9.

Associations of triglyceride glucose-body mass index and the combination of sedentary behavior and physical activity with risks of all-cause mortality and myocardial infarction: a cohort study from the UK biobank.

Zhu Y, Yao T, Tian L, Zhang Y, Ke Q Cardiovasc Diabetol. 2025; 24(1):102.

PMID: 40025584 PMC: 11871674. DOI: 10.1186/s12933-025-02652-5.

Association between estimated glucose disposal rate with the all-cause and cause-specific mortality among the population with cardiometabolic syndrome.

Fu C, Li Y, Gao X, Gong Y, Wang H, Wang G Diabetol Metab Syndr. 2025; 17(1):73.

PMID: 40012030 PMC: 11863411. DOI: 10.1186/s13098-025-01636-5.

References

DeFronzo R, Triplitt C, Qu Y, Lewis M, Maggs D, Glass L . Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care. 2010; 33(5):951-7. PMC: 2858197. DOI: 10.2337/dc09-1521. View

Clarke G, Solis-Herrera C, Molina-Wilkins M, Martinez S, Merovci A, Cersosimo E . Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes. Diabetes Care. 2017; 40(11):1530-1536. PMC: 5652586. DOI: 10.2337/dc17-0078. View

Miyazaki Y, DeFronzo R . Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metab. 2008; 10(12):1204-11. DOI: 10.1111/j.1463-1326.2008.00880.x. View

Rossetti L, Smith D, Shulman G, Papachristou D, DeFronzo R . Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987; 79(5):1510-5. PMC: 424427. DOI: 10.1172/JCI112981. View

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Pettiti M, Natali A . Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. Diabetologia. 2003; 46(9):1211-9. DOI: 10.1007/s00125-003-1169-6. View

Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo R . Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab. 2006; 292(3):E871-83. DOI: 10.1152/ajpendo.00551.2006. View

Wilson P, DAgostino R, Levy D, Belanger A, Silbershatz H, Kannel W . Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97(18):1837-47. DOI: 10.1161/01.cir.97.18.1837. View

Hsueh W, Lyon C, Quinones M . Insulin resistance and the endothelium. Am J Med. 2004; 117(2):109-17. DOI: 10.1016/j.amjmed.2004.02.042. View

10.

Allison D, Fontaine K, Manson J, Stevens J, VANITALLIE T . Annual deaths attributable to obesity in the United States. JAMA. 1999; 282(16):1530-8. DOI: 10.1001/jama.282.16.1530. View

11.

Kern M, Kloting N, Mark M, Mayoux E, Klein T, Bluher M . The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. Metabolism. 2016; 65(2):114-23. DOI: 10.1016/j.metabol.2015.10.010. View

12.

Nolan C, Ruderman N, Kahn S, Pedersen O, Prentki M . Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes. Diabetes. 2015; 64(3):673-86. PMC: 4338588. DOI: 10.2337/db14-0694. View

13.

Wilkes J, Hevener A, Olefsky J . Chronic endothelin-1 treatment leads to insulin resistance in vivo. Diabetes. 2003; 52(8):1904-9. DOI: 10.2337/diabetes.52.8.1904. View

14.

Stout R . The effect of insulin on the incorporation of sodium (1- 14 C)-acetate into the lipids of the rat aorta. Diabetologia. 1971; 7(5):367-72. DOI: 10.1007/BF01219472. View

15.

Flegal K, Kit B, Orpana H, Graubard B . Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013; 309(1):71-82. PMC: 4855514. DOI: 10.1001/jama.2012.113905. View

16.

Sasaoka T, Ishiki M, Sawa T, Ishihara H, Takata Y, Imamura T . Comparison of the insulin and insulin-like growth factor 1 mitogenic intracellular signaling pathways. Endocrinology. 1996; 137(10):4427-34. DOI: 10.1210/endo.137.10.8828504. View

17.

Bhatt B, Dube J, Dedousis N, Reider J, ODoherty R . Diet-induced obesity and acute hyperlipidemia reduce IkappaBalpha levels in rat skeletal muscle in a fiber-type dependent manner. Am J Physiol Regul Integr Comp Physiol. 2005; 290(1):R233-40. DOI: 10.1152/ajpregu.00097.2005. View

18.

Sasaoka T, Rose D, Jhun B, Saltiel A, Draznin B, Olefsky J . Evidence for a functional role of Shc proteins in mitogenic signaling induced by insulin, insulin-like growth factor-1, and epidermal growth factor. J Biol Chem. 1994; 269(18):13689-94. View

19.

Kastorini C, Milionis H, Esposito K, Giugliano D, Goudevenos J, Panagiotakos D . The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. J Am Coll Cardiol. 2011; 57(11):1299-313. DOI: 10.1016/j.jacc.2010.09.073. View

20.

Anderson J, Konz E, Frederich R, Wood C . Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr. 2001; 74(5):579-84. DOI: 10.1093/ajcn/74.5.579. View